Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial).
molecular analysis
mucosal
multiple myeloma
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
01
09
2020
revised:
22
10
2020
accepted:
26
10
2020
entrez:
18
7
2022
pubmed:
8
11
2020
medline:
8
11
2020
Statut:
epublish
Résumé
Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib-thalidomide-dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression-free survival (PFS) (10.2 vs 8.5 months,
Identifiants
pubmed: 35846090
doi: 10.1002/jha2.130
pii: JHA2130
pmc: PMC9176146
doi:
Types de publication
Journal Article
Langues
eng
Pagination
99-103Informations de copyright
© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
HL: Research Funding: Takeda, Amgen; Speaker's Bureau: Takeda, Amgen, Janssen, BMS, Celgene; Consultancy Fees: PharmaMar; SK: Consultancy Fees: Takeda; EG: Honoraria: Takeda, Janssen, Amgen, BMS; Advisory Board: Takeda, Janssen, Amgen, Novartis; AP: Honoraria, Advisory Board: Takeda, Celgene; KW: Honoraria: Novartis, Janssen, Celgene, Amgen, Onyx, Takeda, BMS; Consultancy Fees: Janssen, Celgene, Amgen, BMS, Takeda, Onyx; RG: Research Funding: Roche, Celgene, Takeda, Novartis; Personal Fees: Roche, Takeda, BMS, Amgen; HE: Speaker's Bureau, Advisory Board: Celgene, Janssen, Amgen, BMS, Novartis; Consultancy Fees, Honoraria: Celgene, Janssen, BMS, Amgen; WW: Research Funding: Amgen, BMS, Celgene, Janssen, Novartis, Roche, Takeda; Advisory Board/Consultancy fees: Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, Roche, Sandoz, Takeda; The remaining authors declare no competing financial interests.
Références
J Clin Med. 2019 Oct 22;8(10):
pubmed: 31652577
Nat Commun. 2018 Dec 3;9(1):4832
pubmed: 30510245
Nat Microbiol. 2017 Aug 24;2:17121
pubmed: 28836573
Nature. 2013 Dec 19;504(7480):451-5
pubmed: 24226773
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
N Engl J Med. 2020 Feb 27;382(9):822-834
pubmed: 32101664
Med Sci Monit. 2019 Nov 03;25:8269-8280
pubmed: 31678982
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Br J Cancer. 2019 Oct;121(9):751-757
pubmed: 31558804
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Blood. 2012 Jul 12;120(2):376-85
pubmed: 22451422
Blood Adv. 2019 Jul 9;3(13):2040-2044
pubmed: 31289031
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Database (Oxford). 2010 Jul 06;2010:baq013
pubmed: 20624719
Genome Med. 2016 Apr 28;8(1):49
pubmed: 27121964